Institutional Repository UDD

Validación argentino-chilena de la versión en espanol ˜ del test Addenbrooke’s Cognitive Examination III para el diagnóstico de demencia

Show simple item record

dc.contributor.author Bruno, D
dc.contributor.author Slachevsky, Andrea
dc.contributor.author Fiorentino, N
dc.contributor.author Rueda, D
dc.contributor.author Bruno, G
dc.contributor.author Tagle, A
dc.contributor.author Olavarria, L
dc.contributor.author Flores, P
dc.contributor.author Lillo, P
dc.contributor.author Roca, M
dc.contributor.author Torralva, T
dc.date.accessioned 2018-01-18T15:29:52Z
dc.date.available 2018-01-18T15:29:52Z
dc.date.issued 2017
dc.identifier.citation Neurologia. 2017 Aug 30. pii: S0213-4853(17)30250-5 es_CL
dc.identifier.uri http://dx.doi.org/10.1016/j.nrl.2017.06.004 es_CL
dc.identifier.uri http://hdl.handle.net/11447/1918
dc.description.abstract BACKGROUND: The Addenbrooke's Cognitive Examination III (ACE-III), an adaptation of the ACE cognitive screening test, has been demonstrated to have high sensitivity and specificity in detecting cognitive impairment in patients with dementia and other neurological and psychiatric disorders. Although the Spanish-language version of the ACE-III has already been validated in Spain, it is yet to be validated in Latin America. The aim of this study was to validate the ACE-III test in an Argentinean and Chilean population. METHODS: ACE-III was administered to 70 patients with Alzheimer disease, 31 patients with behavioural variant frontotemporal dementia, and a control group of 139 healthy volunteers. Participants were recruited at centres in both countries. RESULTS: The Spanish-language version of ACE-III was found to have good internal consistency (Cronbach's alpha=0.87). We found significant differences in total ACE-III scores between patients with Alzheimer disease and controls (p< .05) and between patients with Alzheimer disease and bvFTD (p< .05). With a cut-off point of 86, 98.6% of AD patients, 83.9% of behavioural variant frontotemporal dementia patients, and 84.2% of controls were correctly classified. CONCLUSIONS: This study shows that the Spanish-language version of ACE-III continues to be an effective tool for detecting cognitive dysfunction in patients with dementia. es_CL
dc.format.extent 7 es_CL
dc.language.iso spa es_CL
dc.publisher Sociedad Española de Neurología es_CL
dc.subject ACE-III es_CL
dc.subject Alzheimer disease es_CL
dc.subject Cognitive impairment es_CL
dc.subject Dementia es_CL
dc.subject Frontotemporal dementia es_CL
dc.subject Screening es_CL
dc.title Validación argentino-chilena de la versión en espanol ˜ del test Addenbrooke’s Cognitive Examination III para el diagnóstico de demencia es_CL
dc.title.alternative Argentinian/Chilean validation of the spanish language version of Addenbrooke's cognitive examination III for diagnosing dementia es_CL
dc.type Artículo es_CL


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Browse

My Account